• Scientists test G. vaginalis treatment

Bioanalytical

Scientists test G. vaginalis treatment

Posted by Neil Clark

Scientists have used quantitative analysis processes to determine whether neutralising recombinant antibodies will become a novel treatment for in bacterial vaginosis.

In a study published by BMC Biotechnology journal, a team from Lithuania noted that bacterial vaginosis is often caused by gardnerella vaginalis colonising the vaginal tract, which produces protein toxin vaginolysin (VLY).

Inhibition of VLY-mediated cell lysis by antibodies may have important physiological relevance., with the team suggesting that recombinant single-chain antibodies may have the desired effect.

Using quantitative analysis processes, the scientists tested the antigen-binding activity of purified single-chain variable fragments of immunoglobulins (scFvs) and calculated apparent Kd values and found that the neutralizing potency of scFvs were in agreement with those of parental full-length antibodies.

"G. vaginalis caused infections continue to be a worldwide problem, therefore neutralizing recombinant antibodies may provide novel therapeutic agents useful in the treatment of bacterial vaginosis and other diseases caused by G. vaginalis," the report noted.


Events

SCM-11

Jan 20 2025 Amsterdam, Netherlands

Medlab Middle East

Feb 03 2025 Dubai, UAE

China Lab 2025

Feb 05 2025 Guangzhou, China

PITTCON 2025

Mar 01 2025 Boston, MA, USA

H2 Forum

Mar 04 2025 Berlin, Germany

View all events